Opin­ion: It shouldn’t mat­ter who the FDA com­mis­sion­er is when it comes to con­tro­ver­sial drug ap­proval de­ci­sions

4 years ago
FDA+
Opinion

PureTech's video game for AD­HD gets big Se­ries D fi­nanc­ing; Day One in­creas­es term sheet ahead of ex­pect­ed IPO

4 years ago
News Briefing

Un­der-the-radar NiKang Ther­a­peu­tics bursts on­to the scene with $200M Se­ries C from in­vestors that screams IPO

4 years ago
Financing

‘In­ac­cu­ra­cies’ push FDA to re­verse Trump-era ter­mi­na­tion of its Un­ap­proved Drugs Ini­tia­tive

4 years ago
Pharma
FDA+

Tra­vere takes a hit as FDA staffers shoo off their ac­cel­er­at­ed drug pitch

4 years ago
FDA+

Covid-19 roundup: French in­flu­encers tar­get­ed in mis­in­for­ma­tion cam­paign against Pfiz­er; As­traZeneca and the EU le­gal ...

4 years ago
Coronavirus

Omid Farokhzad’s biotech in­sid­ers SPAC opens the deal win­dow with $200M to play with

4 years ago
Financing

Eight bets in, Spain's Ys­ios of­fi­cial­ly ties a bow around €216M fund

4 years ago
Financing

Tim Lu is ready to take his AI-fo­cused biotech to the next lev­el with first big fundrais­ing round

4 years ago
Financing
AI

Three years af­ter piv­ot­ing out of dis­as­ter, Vec­tura gets a $1.4B pri­vate eq­ui­ty buy­out

4 years ago
Deals

Hunt­ing a T-cell cure for sol­id tu­mors, Rick Klaus­ner’s Lyell steers to Nas­daq — with big dreams and fresh ...

4 years ago
Financing

FDA clos­es the door on EUA re­quests for some fu­ture Covid-19 vac­cines

4 years ago
FDA+
Coronavirus

Deaths of mon­keys spur clin­i­cal hold for rare dis­ease biotech's lead and on­ly drug — and a $95M cash in­fu­sion goes ...

4 years ago
FDA+

Proven­tion Bio roller­coast­er con­tin­ues with gen­er­al­ly pos­i­tive re­marks from FDA ahead of Thurs­day’s ad­comm

4 years ago
Pharma
FDA+

New da­ta point to how Keytru­da changed lung can­cer treat­ment; A Hous­ton biotech earns ear­ly back­ers in quest to turn ...

4 years ago
News Briefing

Spurred on by Mod­er­na and Pfiz­er's suc­cess, a Bel­gian biotech has big am­bi­tions for its self-am­pli­fy­ing RNA vac­cine ...

4 years ago
Financing
Coronavirus

Days af­ter FDA clears C3 drug, Apel­lis spot­lights ex-US PhI­II win among pa­tients who haven't tak­en Soliris

4 years ago
R&D
Pharma

An­a­lysts throw cold wa­ter on Ex­elix­is and Roche's prostate can­cer da­ta, putting the pair a fur­ther step be­hind ...

4 years ago
R&D

Covid-19 roundup: Mod­er­na says vac­cine safe, ef­fec­tive in ado­les­cents; CEPI backs a syn­thet­ic bi­ol­o­gy vac­cine for ...

4 years ago
Coronavirus

Black­stone en­lists a mur­der­ers' row of ad­vi­sors, in­clud­ing ex-Sanofi CEO Olivi­er Brandi­court, to steer life sci­ences ...

4 years ago
People
Financing

UK be­gins in­quiry in­to As­traZeneca's $39B buy­out of Alex­ion

4 years ago
Deals
Pharma

Al­loy and Pyx­is spin out new 'com­pa­ny' around high-risk I/O, im­munol­o­gy tar­gets

4 years ago
Startups
Deals

Pieris inks res­pi­ra­to­ry part­ner­ship with Genen­tech, adding an­oth­er to slate of mile­stone-heavy deals

4 years ago
Deals

RNA: From the mes­sen­ger to the med­i­cine

4 years ago
Biotech Voices
First page Previous page 688689690691692693694 Next page Last page
A service from the Financial Times